secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2023-09-28T23:59:59+00:00
Accession:  0001104659-23-104743
Event type: other_material
Sentiment:  negative
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode closes $8.5M public offering; issues 16.9M shares/pre-funded warrants at $0.51
--------------------------------------------------------------------------------

- Gross proceeds ~$8.5M from sale of 700K common shares and 16.2M pre-funded warrants at $0.51 per share/warrant, including partial over-allotment exercise.
- Use of proceeds for clinical trials of lead candidate TTX-MC138 and working capital.
- ThinkEquity sole book-runner; granted 45-day over-allotment option (partially exercised) plus 843K underwriter warrants at $0.6375 per share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465923104743/0001104659-23-104743-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465923104743/tm2327131d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-104743

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer